CG Oncology, Inc.

CGON

Explore Our Financial Data > Companies > CG Oncology, Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	CGON
CIK	0001991792
SIC	2836
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Biological Products, Except Diagnostic Substances

Contact

Address	400 SPECTRUM CENTER DRIVE, SUITE 2040, IRVINE, CA, 92618
Website	cgoncology.com
Phone	(949) 419-6203
CEO	Arthur Kuan
Employees	N/A

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	N/A
Pre-Tax Income	N/A
Net Income	N/A
Net Income to Common	N/A
EPS	N/A

View All

Balance Sheet

Cash	N/A
Assets	N/A
Liabilities	N/A
Common Equity	N/A
Liabilities & Equity	N/A

View All

Cash Flow Statement

Net Income	N/A
Cash From Operating Activities	N/A
Cash From Investing Activities	N/A
Cash From Financing Activities	N/A
Change in Cash	N/A

View All

Calculations

NOPAT	N/A
EBITDA	N/A
Price to Earnings	N/A
Price to Book	N/A
ROE	N/A

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - - Initiated CORE-008 Cohort CX evaluating the combination of cretostimogene and gemcitabine in patients with high-risk (HR) BCG-exposed NMIBC - - Announced unanimous verdict that CG Oncology owes no future royalties or other payments to ANI Pharmaceuticals - IRVINE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE)

Article Link

Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates

Arbutus (ABUS) delivered earnings and revenue surprises of +150.00% and +496.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Article Link

CG Oncology, Inc. (CGON) Reports 75.5% Complete Response in Bladder Cancer Trial

We recently compiled a list of 11 Best Future Stocks to Buy Now. CG Oncology, Inc. stands sixth on our list. CG Oncology, Inc. (NASDAQ:CGON) is a late-stage clinical biopharmaceutical company developing bladder-sparing immunotherapies, with a primary focus on cretostimogene grenadenorepvec, a targeted oncolytic virus therapy for bladder cancer. Their lead program targets high-risk, BCG-unresponsive […]

Article Link

Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals

IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that a jury in the Superior Court of the State of Delaware (the “Court”) unanimously found in favor of CG Oncology on all claims in a March 2024 lawsuit brought by ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI”). The jury unan

Article Link

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide (https://ibn.fm/dyQrw) with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with cancer every year. Despite significant progress made in treating the disease, there is still a desperate need — and an enormous market potential — for new and more effective cancer drugs. Calidi Biotherapeutics Inc. (NYS

Article Link